Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Follicular Lymphoma, Grade III: early-phase trial registry

1 of 1 indexed Follicular Lymphoma, Grade III trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Follicular Lymphoma, Grade III: 1 US clinical trial tracked, 1 recruiting.

Follicular Lymphoma, Grade III is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is New York Medical College, running 1 of these trials.

Enrollment posture brief

Registry condition follicular-lymphoma-grade-iii

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Follicular Lymphoma, Gra (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Follicular Lymphoma, Grade III

Follicular Lymphoma, Grade III lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Follicular Lymphoma, Grade III on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Follicular Lymphoma, Grade III is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Follicular Lymphoma, Grade III records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Liposomal ARA-C Drug
1 trials
Ifosfamide Drug
1 trials
Etoposide Drug
1 trials
Carboplatin Drug
1 trials
Obinutuzumab Drug
1 trials

US sites by state

Facility locations filed on Follicular Lymphoma, Grade III trials. A trial with sites in several states counts in each.

New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Follicular Lymphoma, Grade III page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Follicular Lymphoma, Grade III trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • New York Medical College sponsors the most Follicular Lymphoma, Grade III trials on record, review their full trial history before evaluating a specific study. See New York Medical College's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Follicular Lymphoma, Grade III condition card totals 1 registered trials; most-linked intervention Liposomal ARA-C; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.